Aurobindo Pharma
Aurobindo Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #59 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Aurobindo Pharma Q1 FY27 key numbers
- Revenue
- Consolidated revenues increased by 16% YoY to Rs. 9,150 crores, driven by broad-based business performance.
As stated in Aurobindo Pharma's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
From Aurobindo Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Consolidated revenues increased by 16% YoY to Rs. 9,150 crores, driven by broad-based business performance.
- Formulation business grew 17% YoY, contributing ~89% of revenues.
- U.S. revenues up 8.1% YoY with 10 new product launches and 9 ANDA filings in the quarter.
- European business expects double-digit growth in FY27 with continued new launches.
- Growth markets increased 38% YoY, with expansion in countries like Indonesia, China, and Canada.
- FY27 guidance: double-digit revenue growth, EBITDA margins above 21%, EBITDA exceeding Rs. 8,000 crores.
- Biosimilar and biological CMO businesses are long-term growth drivers.
- TheraNym CDMO revenues expected to start from 2028 (~$150-$200 million by 2032) with 35-50% EBITDA margins.
2 more points from Aurobindo Pharma's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aurobindo Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
- The Lannett acquisition has provided substantial manufacturing capacity and strategic benefits with minimal additional CAPEX needed in the short term.
- Aurobindo has scope for expansion at existing facilities, including Lannett and Aurolife units, and has a reserve facility that can be quickly brought online if required.
- The recent acquisition of A1 Biochem (a CRO) complements existing API capabilities, aiming to develop an integrated CRDMO, accelerating growth by 3-5 times over 3-5 years versus greenfield investment taking 5 years.
2 more points from Aurobindo Pharma's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aurobindo Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Aurobindo Pharma's call on order book
Create a free account to keep reading this call
What the Q1 FY27 call signalled
1 of 3 strong
Aurobindo Pharma — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹8.9K Cr, net profit ₹921 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aurobindo Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aurobindo Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aurobindo Pharma Q1 FY27 results?
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
What is Aurobindo Pharma share price analysis?
Aurobindo Pharma currently shows a below-average growth signal. The stock trades at a P/E of 24.9 with a market cap of ₹94,165 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aurobindo Pharma planning capital expenditure?
Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
Keep Aurobindo Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.